Sensitivity of the modified Children's Yale–Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials. (February 2016)

• Record Type: Journal Article
• Authors: Scahill, Lawrence; Sukhodolsky, Denis G; Anderberg, Emily; Dimitropoulos, Anastasia; Dziura, James; Aman, Michael G; McCracken, James; Tierney, Elaine; Hallett, Victoria; Katz, Karol; Vitiello, Benedetto; McDougle, Christopher
• Is Part Of: Autism. Volume 20:Number 2(2016)
• Page Start: 145
• Page End: 152
• Publication Date: 2016-02
• Subjects: autism spectrum disorder -- clinical trials -- outcome measurement -- repetitive behavior -- risperidone; Autism -- Periodicals; Autism in children -- Periodicals; 616.85882005
• DOI: 10.1177/1362361315574889
• Languages: English
• ISSNs: 1362-3613

Abstract

Repetitive behavior is a core feature of autism spectrum disorder. We used 8-week data from two federally funded, multi-site, randomized trials with risperidone conducted by the Research Units on Pediatric Psychopharmacology Autism Network to evaluate the sensitivity of the Children's Yale–Brown Obsessive Compulsive Scale modified for autism spectrum disorder to detect change with treatment. Study 1 included 52 subjects assigned to placebo and 49 subjects to risperidone under double-blind conditions. In Study 2, 49 subjects received risperidone only and 75 subjects received risperidone plus parent training. The combined sample consisted of 187 boys and 38 girls (aged 4–17 years). At the medication-free baseline, the internal consistency on the Children's Yale–Brown Obsessive Compulsive Scale modified for autism spectrum disorder total score was excellent (Cronbach's alpha = 0.84) and the mean scores were similar across the four groups. Compared to placebo in Study 1, all three active treatment groups showed significant improvement (effect sizes: 0.74–0.88). There were no differences between active treatment groups. These results indicate that the Children's Yale–Brown Obsessive Compulsive Scale modified for autism spectrum disorder has acceptable test–retest as evidenced by the medium to high correlations in the placebo group and demonstrated sensitivity to change with treatment.